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Background: Among different resistance mechanisms in Mycobacterium tuberculosis
(MTB), efflux pumps may have a role in drug-resistance property of MTB. So, the aim of
this study was to compare the relative overexpression of two important efflux pump genes,
drrA and drrB, among MTB isolates from TB patients.
Methods: A total of 37 clinical isolates of confirmed MTB isolates were analyzed. Drug
susceptibility testing (DST) was performed using the conventional proportional method.
Real-time semiquantitative PCR profiling of the efflux pump genes of drrA and drrB was
performed for clinical isolates. The receiver operating curve (ROC) analysis for differentia-
tion of resistant from susceptible isolates on the basis of efflux pump expression fold changes
was also performed.
Results: According to DST, 16 rifampin (RIF) monoresistant, 3 isoniazid (INH) monore-
sistant, 5 multidrug-resistant (MDR) and 13 pan-susceptible isolates of MTB were evaluated
for gene expression. The highest values of drrA and drrB gene expression fold changes were
seen in MDR isolates, which were significant in comparison with susceptible isolates and
H37Rv reference strain. By using comparative ROC analysis, the obtained cutoff point for
drrA and drrB gene overexpression was the folds of >1.6 and >2.3, respectively.
Conclusion: The results of the present study confirm the role of DrrA-DrrB efflux pump in
antibiotic resistance in clinical MTB isolates. As the large number of efflux pumps are
located in the cell envelope of MTB, we cannot correlate a single efflux pump overexpres-
sion to the drug-resistance phenotype, unless all the pumps simultaneously investigated.
Keywords: Mycobacterium tuberculosis, multidrug resistance, efflux pump regulators,
Isoniazid, Rifampin
Introduction
Tuberculosis (TB) caused byMycobacterium tuberculosis (MTB) is the major cause
of morbidity and mortality worldwide.1 According to the recent WHO report,2 TB
is the ninth mortality cause in the world, and it was estimated that 10 million people
suffered from TB in 2017; among them, 9% were HIV positive. Nowadays, the
major challenge in TB control and treatment is the emergence of different forms of
drug-resistant MTB isolates, including multidrug resistance (MDR), defined as TB
resistant to at least isoniazid (INH) and rifampin (RIF), and extensively drug
resistance (XDR), which is defined as MDR-TB plus resistance to any
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fluoroquinolone and at least one second-line injectable
aminoglycoside antibiotics.3,4 In 2016, about 600,000
RIF-resistant (RR) new cases and 490,000 MDR isolates
were recognized.2 Globally, 4.1% of new cases and 19%
of previously treated TB patients are estimated to have
RR-TB or MDR-TB, and about 6.2% of MDR-TB cases
have additional drug resistance of XDR.5 Treatment of
MDR and XDR-TB with currently available anti-TB
drugs needs a longer time, associated with high costs,
and has toxic side effects and treatment outcomes are
often poor.6
The mode of action of RIF is binding to the β-subunit
of RNA polymerase and inhibiting the elongation of
mRNA molecule. INH metabolically is active against
live bacteria and inhibits mycolic acid synthesis.7 Apart
from known mutations in genes conferring resistance to
INH and RIF, efflux pump activity was recently recog-
nized to play a significant role in the development of drug-
resistant phenotypes in MTB.8–10 Efflux pumps extrude
many substrates including peptides, lipids, ions, drugs
and antibiotics, from the intracellular environment into
the extracellular space.4 Efflux-mediated drug resistance
in M. tuberculosis could be due to one or more efflux
pumps working alone or in coordination.11 The overex-
pression of efflux pumps can significantly decrease the
intracellular concentration of many antibiotics and conse-
quently reduce the efficacy of drugs.10
Efflux pumps can be divided into two main classes of
ATP-binding cassette (ABC) transporters and secondary
multidrug transporters. The latter, which include the
majority of clinically relevant efflux systems, can be sub-
divided into four superfamilies based primarily on homol-
ogy at the levels of primary and secondary structures.12
These superfamilies are the major facilitator superfamily
(MFS), multidrug and toxic compound extrusion (MATE),
resistance-nodulation-division (RND) and small multidrug
resistance (SMR) families. The RND, SMR, MFS super-
family and ABC transporter have been found in MTB.8 In
MTB, the genes encoding the predicted ABC transporters
occupy about 2.5% of the genome.13
Two transnationally coupled open-reading frames, drrA
(Rv 2936) and drrB (Rv2937), encode an ABC-type trans-
porter, with drrA encoding the nucleotide-binding domain
and drrB encoding the membrane-integral component. In
fact, drrA and drrB are important because of their potency
in making antibiotic resistant phenotype against structu-
rally unrelated drugs. Studies have shown that after
inhibition of ABC transporters, the resistant phenotype is
changed into the sensitive type.14
The aim of this study was to compare the relative
overexpression of two important efflux pump genes, drrA
and drrB, related to ABC transporter in order to evaluate
the role of these genes in drug resistance among MTB
isolates from TB patients.
Materials And Methods
Bacterial Strains
The MTB strains selected for this study were isolated from
samples of confirmed pulmonary TB patients referred to
Regional Tuberculosis Laboratory of Khuzestan province,
Iran, during a 2-year period, from February 2015 to
February 2017. The preliminary proposal of the work was
approved in joint Institutional Review Board (IRB) and
Ethics Committee of the Ahvaz Jundishapur University of
Medical Sciences, Iran, and the necessary permission was
granted for sample collection. Moreover, as part of the
Regional Centers’ policy, referred patients were requested
to sign the informed consent in case that their samples are
used for research purposes apart from routine clinical
investigation.
The strains were identified as MTB based on acid-fast
staining, growth on Lowenstein–Jensen (LJ) medium and
standard biochemical identification tests.15
DNA Extraction And PCR Amplification
DNAwas extracted fromMTB isolates grown on LJ medium
by using a simple boiling method as described earlier.16 The
extracted DNAs were molecularly confirmed as belonging to
MTB complex in the next step, by IS6110- based PCR
amplification, employing primers which amplify a 123 bp
fragment of sequence as described previously.17
Drug Susceptibility Testing (DST)
For investigating the antimicrobial susceptibility of MTB
isolates, DST was performed using the standard propor-
tional method according to the clinical and Laboratory
Standard Institute (CLSI) guideline.18 In brief, 0.2 μg/mL
INH and 40 μg/mL RIF (Sigma Aldrich, Steinheim am
Albuch, Germany) antibiotic concentrations were incorpo-
rated into LJ medium followed by inoculation of a pre-
adjusted bacterial suspension equal to 0.5 McFarland.
MTB standard strain of H37Rv (ATCC 27294) was used
as a reference strain. Susceptibility was defined as no or
<1% growth on LJ medium containing drugs as compared
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with the control medium. In total, 24 drug-resistant and 13
randomly selected drug-susceptible MTB isolates were
selected for further investigation.
The isolates were divided into two groups as per DST
results: the susceptible isolates and the MTB isolates with
various resistance phenotypes, including RIF monoresis-
tance, INH mono resistance or isolates resistant to both
INH and RIF (MDR phenotype).
Real-Time Semiquantitative PCR
(RT-sqPCR)
RNA Extraction
Total RNA was extracted from clinical MTB isolates using
High Pure RNA Isolation Kit (Roche Diagnostics, Mannheim,
Germany), according to the manufacturer’s instructions and
treated with DNase Ι (Invitrogen Corporation, Carlsbad, CA,
USA). The concentration and quality of isolated total RNA
were evaluated using Nanodrop spectrophotometer (Thermo
Fischer Scientific Inc., Waltham, MA, USA) at A260/A280.
PCR amplification of the polA gene was done to assess possi-
ble DNA contamination, using the total RNA as a template.
Only RNA with no visible amplified products was used for
experiments.
Complementary DNA (cDNA) Library Synthesis
The cDNA was synthetized using PrimeScript RT reagent
Kit according to the manufacturer’s recommendations
(Takara Bio Inc., Shiga, Japan). Reverse transcription
steps were as follows: 37°C for 10 mins, 42°C for 30 mins
and 70°C for 5 mins. The synthesized cDNA was main-
tained at −80°C until use.
RT-sqPCR was performed to evaluate the overexpres-
sion of drrA and drrB efflux pump genes according to a
previous report.19 polA was used as a housekeeping gene
for normalization. The primer sequences for drrA, drrB
and polA genes are described in Table 1.
The master-mix was prepared according to the kit manu-
facturer’s instruction (Takara Bio Inc.). RT-sqPCR was done
in an ABI Step-One thermocycler (Applied Biosystem,
Scientific, Darmstadt, Germany) with the following amplifica-
tion program: initial denaturation at 95°C for 5 mins and 45
cycles of denaturation at 95°C for 15 s, annealing at 60°C for
30 s, extension at 72°C for 20 s and a final extension at 72°C
for 5 mins and an additional step at 50°C for 15 s followed by
melt analysis (50–99°C). The RT-sqPCR reactions were per-
formed in triplicate samples using total RNA from three
independent cultures for each strain. Differential expression
was done by comparing the normalized Ct values (2−ΔΔCt) of
all the biological replicates between two groups of samples
using the Livak equation.20 We also used the relative expres-
sion software tool (REST 2009) to confirm the relative expres-
sion values.
Statistical Analysis
Comparison of gene fold changes among different studied
groups on the basis of DST results was done using Mann–
Whitney test because of data distribution abnormality after
Kolmogorov–Smirnov test. To evaluate the accuracy of
drrA or drrB gene folds, receiver operating curve (ROC)
analysis was used for estimation of the proper cutoff
points, positive and negative predictive values (PPV and
NPV) of fold change as a decision-making tool for clinical
application of drrA and drrB genes using RT-sqPCR
method. Statistical analysis and calculations were done
using MedCalc® software version 15.8.
Results
In this study, 37 clinical isolates which had been charac-
terized as MTB by using standard phenotypic tests and
IS6110-PCR amplification were entered the study.
According to DST, drug-resistance pattern of the isolates
were as follows: 16 RIF monoresistant, 3 INH monoresis-
tant, 5 MDR and 13 pan-susceptible isolates.
Table 1 The Sequence Of Primers Of The Genes Used In This Study
No. Gene Primer Sequence (5′→3′) Amplicon Size (bp)
1 drrA Forward TAGACATCGCGTGCGGATTGGT 147
Reverse GCGTGGTCAACAACGTGGCAAT
2 drrB Forward TCGCCAGCAACTTAGGGCAATACA 233
Reverse TCCGATGACGTAGCCGCAAACTAG
3 polA Forward TCCGATGACGTAGCCGCAAACTAG 181
Reverse GTCGTGGTTGGACCTTGGAGGG
Dovepress Khosravi et al
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In order to investigate the involvement of drrA and
drrB efflux pump genes in the drug resistance of MTB
clinical isolates, the relative expression profiles (fold
changes) of these genes were examined by RT-sqPCR,
using H37Rv as the reference strain. The results of DST
and expression fold changes of putative efflux pump genes
for each isolate are presented in Table 2.
The majority of resistant phenotypes overexpressed
both genes more than twofolds, while the pan-susceptible
isolates showed less than twofold expression which was
not significant compared to H37Rv reference strain. All
MDR isolates overexpressed both drrA and drrB genes,
which was significant in comparison with susceptible iso-
lates and H37Rv reference strain (P values 0.009 and 0.09,
respectively), while 9 out of 16 RIF monoresistant isolates
(56.25%) showed overexpression of drrA and 14 (87.5%)
of these isolates showed overexpression of drrB gene; both
were significant as well (P values for both genes were
0.025). INH monoresistant isolates overexpressed both
genes; however, due to the lower number of these isolates,
we did not demonstrate significant differences compared to
susceptible isolates (Table 3).
The gene expression fold changes were significantly dif-
ferent among MTB isolates categorized according to their
DST results (P= 0.000173 for drrA gene and P= 0.000115 for
drrB gene). Figures 1 and 2 represent the comparative box-
plot of drrA and drrB gene fold changes amongMTB isolates
in different antibiotic resistance patterns. Both MDR and
INH monoresistant isolates had significantly high expression
fold changes of drrA in comparison with pan-susceptible
isolates (Figure 1), and as the figure shows, the highest and
the lowest expression values belonged to the MDR and pan-
susceptible isolates, respectively, in comparison with stan-
dard MTB strain of H37Rv.
For drrB gene, though the expression fold changes were
higher in RIF monoresistant isolates, all MDR and INH
monoresistant isolates showed high expression fold changes
for drrB similar to drrA gene (Figure 2). The highest and the
Table 2 The Results From Phenotypic Drug Susceptibility Testing And Relevant drrA And drrB Gene Expression Fold Changes For
MTB Isolates
Patients
No.
Resistance
Pattern
drrA Fold
Changes
drrB Fold
Changes
Patient
No.
Resistance
Pattern
drrA Fold
Changes
drrB Fold
Changes
1 RIF 6.7 4.8 20 S 1.3 2.3
2 MDR 23.62 10.7 21 RIF 0.2 2.9
3 MDR 18.53 4.07 22 S 1.6 0.6
4 MDR 23.51 4.1 23 S 0.4 1.2
5 MDR 27.93 5.23 24 S 0.3 1.4
6 MDR 19.8 3.08 25 S 0.3 1.9
7 RIF 23.19 4.15 26 S 0.2 1.02
8 RIF 0.98 3.34 27 RIF 0.5 3.05
9 RIF 4.8 4.24 28 RIF 0.3 15.46
10 RIF 3.06 1.9 29 S 0.4 2.3
11 RIF 12.7 3.6 30 INH 4.7 2.3
12 RIF 17.86 3.5 31 INH 6.9 7.1
13 RIF 27.17 2.9 32 S 0.4 0.38
14 RIF 13.38 2.1 33 INH 6.01 5.4
15 RIF 5.6 0.1 34 S 0.1 0.2
16 S 1.1 2.1 35 S 0.2 0.3
17 RIF 0.4 5.07 36 S 0.2 0.3
18 RIF 0.7 2.5 37 S 0.1 0.01
19 RIF 0.3 4.01
Abbreviations: RIF, rifampin; INH, isoniazid; MDR, multidrug resistant; S, susceptible.
Table 3 Correlation Of Genes Expression Fold Changes Of drrA
And drrB In Mycobacterium Tuberculosis Isolates With Various
Drug-Resistance Patterns
Resistance
Phenotype
drrA
Expression
No.(%)
P value drrB
Expression
No.(%)
P value
RIF
monoresistant
9 (56.25) 0.025 14(87.5) 0.025
INH
monoresistant
3 (100) 0.1 3 (100) 0.1
MDR 5 (100) 0.009 5 (100) 0.09
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lowest expression values for drrB gene belonged to theMDR
and pan-susceptible isolates, respectively.
In this work, we have also evaluated drrA and drrB gene
expression fold changes for clinical purposes, using ROC
analysis. This analysis was used to estimate the sensitivity
and specificity, based on calculated cutoff points.
According to DST results, from 37 MTB tested isolates,
13 (35.14%) were susceptible and 24 (64.86%) were resis-
tant to antibiotics. Comparative ROC analysis represented
no significant difference between two genes in view of their
application as diagnostic tools for differentiation of suscep-
tible MTB isolates from resistant ones (Figure 3).
The obtained cutoff point for drrA gene overexpression
was the folds of >1.6 with sensitivity and specificity equal
to 70.83% and 100%, respectively. The best cutoff point
for drrB gene overexpression was the folds of >2.3 with
sensitivity and specificity values equal to 83.33% and
100%, respectively.
Discussion
There are different mechanisms by which the MTB strains
show resistance against antibiotics. The intrinsic resistance
of MTB to most antibiotics is generally attributed to the
low permeability of the mycobacterial cell wall because of
its specific lipid-rich composition and structure.21 Since
the first evidence of active efflux being involved in anti-
biotic resistance, efflux mechanisms have been recognized
to be major players in bacterial drug resistance.13,22 The
antibiotics need to be reached to an effective intracellular
concentration to do their job. However, bacterial efflux
pumps extrude them before they could accumulate to
their antibacterial active concentration. 23
In the present study, we evaluated the expression fold
changes of drrA and drrB genes encoding putative DrrA-
DrrB drug efflux pump belong to ABC transporter, in
MTB isolates. The results demonstrated that RIF and
INH monoresistant and MDR isolates showed meaning-
fully increased expression fold changes compared to sus-
ceptible isolates and H37Rv-susceptible reference strain.
The efflux pump genes of drrA and drrB were shown to be
significantly overexpressed in most of the antibiotic resis-
tant MTB isolates demonstrating the contribution of these
genes to the resistance phenotype of the isolates studied.
Figure 1 The drrA gene expression fold comparison of different groups of MTB
isolates as per DST results.
Figure 2 The drrB gene expression fold comparison of different groups of MTB
isolates as per DST results. Note that a rifampin-resistant isolate showed very high
levels of drrB gene expression which is shown by a dot on the FIGURE as an outlier.
Figure 3 Comparative ROC curve for drrA and drrB genes. Statistical analysis
showed that there is no meaningful difference between drrA and drrB genes con-
sidering diagnostic accuracy (P value= 0.4045).
Dovepress Khosravi et al
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Our findings suggest that the drrA and drrB genes may
have a key role in MDR phenotype of MTB in the same
efflux pump, because all MDR isolates showed high
expression fold changes demonstrated by RT-sqPCR.
In concordant to our study, Jiang et al have reported
that the increased gene expression folds of their tested
efflux pumps are associated with the MDR property in
MTB strains.24 They have tested putative efflux pump
genes including Rv1258c, Rv1410c and Rv1819c and
showed that the first two genes were overexpressed upon
RIF or INH exposure, whereas the last gene was over-
expressed only upon INH exposure. However, their find-
ings were limited to only one clinical isolate, whereas we
have tested 37 clinical MTB isolates.
There are other studies which also have confirmed the
association of different efflux pumps with antibiotic resis-
tance phenotypes of MTB strains.25 The expression of
efflux pumps including Rv2459, Rv3728, and Rv3065 is
reported to be increased in response to MTB exposure to
INH and ethambutol.26 Additionally, in the study of Wang
et al, on 36 isolates of MTB, they reported that the over-
expression of both Rv1217c and Rv1218c genes was the
cause of decreased RIF sensitivity in MIC test, whereas
INH-resistant isolates showed only Rv1218c
overexpression.27 The studies are not limited to MTB, as
other mycobacteria such as M. smegmatis showed to
become MDR when overexpression of Rv0194 occurred.28
In the current study, both drrA and drrB genes showed
expression fold changes mainly for whole MDR and INH
monoresistant isolates showing the role of ABC transpor-
ter efflux pump in resistance of MTB to antibiotics. The
findings were in agreement to another study which stated
that the certain types of efflux pumps may have a central
role for extruding the antibiotics from MTB strains.27
However, based on our findings, it seems that drrB gene
could be a preferred gene for assessing the clinical isolates
for RIF drug resistance as more RIF monoresistant isolates
overexpressed this gene.
Although several classes of efflux pumps in MTB
isolates are investigated previously, there are a few reports
about the expression fold changes of drrA and drrB genes
in clinical isolates of MTB. In one similar study, Li et al
have shown that drrA, drrB, mmr, efpA, jefA, Rv0849,
Rv1634 and Rv1250 genes had high levels of expression
folds in 9 MDR isolates of MTB.19 They have made stress
conditions on isolates using INH and RIF antibiotics fol-
lowed by assessing the folds of efflux pumps, and they
demonstrated that drrA gene folds were overexpressed
followed INH stress, and they have suggested drrA over-
expression as one of the involving factors to INH resis-
tance in MTB accordingly. However, such finding was not
evident for RIF, and none of their isolates showed fold
change of drrA expression levels in response to RIF stress.
Their study was against present study, and Pang et al
report that drrA may induce a low-level resistance to RIF
in MTB isolates.29
Our findings revealed that MDR isolates showed sig-
nificantly high overexpression folds in comparison with
standard H37Rv strain. The highest expression fold
changes in our work were seen for drrA gene, even up to
27.93 folds compared to H37Rv. Furthermore, the highest
value for drrB gene was 15.46 folds in comparison with
H37Rv strain. Calgin et al have compared 10 MDR and 10
susceptible isolates of MTB and reported that drrA and
drrB gene overexpression was 1–2 folds higher than the
H37Rv standard strain.30 On the other hand, Machado et al
have used a cutoff value of 4 or higher folds of gene
expression, compared with drug-unexposed strain and
reported that the efflux pump overexpression levels
would be increased in MTB, after encountering suboptimal
concentrations of antituberculosis drugs.31
As putative efflux pump gene overexpression level is
very important for decision-making and clinical applica-
tion of basic results, in the current work, we have evalu-
ated the accuracy of drrA and drrB gene overexpression as
a guide for drug application in clinical practice. We
believe that this is the first report on the validation of
drrA and drrB gene overexpression folds in relation to
the clinical application of target drugs. ROC analysis on
our results showed that both drrA and drrB are valuable
for TB therapy decision-making and categorizing the drug
susceptibility or resistance of MTB strains. In fact, both
genes showed proper diagnostic accuracy regarding their
sensitivity and specificity. For differentiation of resistant
from susceptible MTB isolates, the calculated cutoff
values had acceptable sensitivity and specificity in addi-
tion to positive and negative predictive values. Thus, we
suggest that the folds >1.6 and >2.3 be considered as
cutoff values for drrA and drrB overexpression folds,
respectively, in future studies.
Our work has some limitations. First, the number of
MDR and INH monoresistant isolates was low, and for
justification of the role of ABC transporter, we need to
extend the duration of our future studies in order to have
more isolates with such resistance phenotypes, and second,
we did not study the efflux pump inhibitors, which
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principally bind to efflux pumps to inhibit drug efflux and
thus enhance the drug effect and reduce drug resistance.
So, further studies on the inhibitors targeting the efflux
pumps of MTB help to understand MTB resistance and to
identify the potential drug target and are of significance in
guiding the development of new anti-TB drugs and opti-
mal combinations as other investigators stated.32
Moreover, a good idea for the future studies could be to
evaluate the global regulators for these pumps and the
effect of the environmental signal on them.
The results of the present study confirm the role of DrrA-
DrrB efflux pump in antibiotic resistance in clinical MTB
isolates. As a large number of efflux pumps are located in the
cell envelope of MTB, we cannot correlate a single efflux
pump overexpression to the drug-resistance phenotype in a
certain MTB cell, unless all the pumps are simultaneously
investigated. However, such studies may suggest that the
potentiation therapies targeting the efflux pumps could be
considered in the future investigations to be included in TB
standard antibiotic therapy. Furthermore, we presented poten-
tial cutoff points of gene expression folds by which molecular
diagnostic laboratories would be able to detect the drug-resis-
tant strains of MTB with proper sensitivity and specificity, in
addition to well positive and negative predictive values.
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